US 12,298,318 B2
Targeting ligands for tau pathology
Parag Parekh, Houston, TX (US); and Ananth Annapragada, Manvel, TX (US)
Assigned to Texas Children's Hospital, Houston, TX (US); and Baylor College of Medicine, Houston, TX (US)
Filed by Texas Children's Hospital, Houston, TX (US)
Filed on Feb. 1, 2023, as Appl. No. 18/163,000.
Application 18/163,000 is a continuation of application No. 17/739,031, filed on May 6, 2022, granted, now 11,614,451.
Application 17/739,031 is a continuation in part of application No. 16/922,762, filed on Jul. 7, 2020, abandoned.
Claims priority of provisional application 63/287,036, filed on Dec. 7, 2021.
Claims priority of provisional application 63/185,317, filed on May 6, 2021.
Claims priority of provisional application 62/871,380, filed on Jul. 8, 2019.
Prior Publication US 2023/0324411 A1, Oct. 12, 2023
Int. Cl. G01N 33/68 (2006.01); A61B 5/055 (2006.01); C12N 15/10 (2006.01); C12N 15/11 (2006.01); C12N 15/115 (2010.01)
CPC G01N 33/6896 (2013.01) [C12N 15/1048 (2013.01); C12N 15/111 (2013.01); C12N 15/115 (2013.01); A61B 5/055 (2013.01); C12N 2310/16 (2013.01); G01N 2800/2821 (2013.01)] 15 Claims
 
1. A method for imagining tau pathology in a subject, the method comprising:
administering to the subject a detectably effective amount of a targeting ligand-liposome conjugate comprising a targeting ligand represented by Compound I:

OG Complex Work Unit Chemistry
wherein the targeting ligand specifically binds to a cell surface marker of tau pathology, and
wherein the targeting ligand is linked to a liposome comprising an imaging agent, and
imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology.